Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2010. The report discloses a specific corporate action regarding a notifiable share interest in Maxygen, Inc., a U.S.-based biopharmaceutical company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the divestiture of an equity stake.
Material Changes
- Divestiture of Maxygen, Inc.: On March 10, 2010, GSK sold its entire holding of 1,433,361 Common shares of Maxygen, Inc.
- Ownership Reduction: GSK's ownership interest in Maxygen decreased from 4.47% to 0% of outstanding Common shares.
- Holding Entities: The shares were held by GSK's wholly owned subsidiaries, Glaxo Group Limited and GlaxoSmithKline Services Unlimited.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves solely as a notification of the completed transaction, with further details referenced in Maxygen's Annual Report on Form 10-K.
Investor Verification Points
- Confirm the sale price and total proceeds from the disposal of 1,433,361 Maxygen shares.
- Review Maxygen's Form 10-K for additional transaction details as referenced in the filing.
- Verify the impact of this divestiture on GSK's consolidated financial statements for the quarter.